Participants 108 174 4
patients with acute myeloid leukemia and myelodysplastic syndromes
Participants 178 227 4
Japanese multicenter randomized, controlled study
Participants 381 488 7
patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy
Participants 713 782 3
patients with MDS or in the remission-induction phase of chemotherapy
Participants 860 878 3
itraconazole group
Participants 891 908 3
fluconazole group
Participants 1007 1056 3
patients with neutrophil counts of >0.1 x 10(9)/L
Participants 1301 1351 5
patients with AML or MDS who received chemotherapy
